This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
'''MiPT''' (also known as '''N-methyl-N-isopropyltryptamine''') is a [[hallucinogen]]ic [[psychoactive class::psychedelic]] drug of the [[chemical class::tryptamine]] class.
Alexander Shulgin first synthesized MiPT and documented it in his book [[TiHKAL]] (''Tryptamines I Have Known and Loved''). It is the methyl analog of [[DiPT]].<ref>https://www.erowid.org/library/books_online/tihkal/tihkal47.shtml Entry in TIHKAL</ref>
'''N-Methyl-N-isopropyltryptamine''' (also known as '''MiPT''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class that produces [[psychedelic]] effects when [[routes of administration|administered]]. It is structurally related to tryptamines like [[DMT]], [[DiPT]], and [[MET]], although it is reported to produce qualitatively different effects. Its effects are generally described as mild, indistinct, and highly variable between users. In contrast to many related tryptamines, it is able to be taken [[orally]].
Today it is either used recreationally or as an [[entheogen]]ic compound and is typically acquired through the use of online [[research chemical]] vendors. It remains relatively uncommon even for a substituted tryptamine and has very little history of human usage.
MiPT was first synthesized and investigated by [[Alexander Shulgin]] and described in his book [[TiHKAL]] ("Tryptamines I Have Known and Loved"). In the commentary, Shulgin notes that "there is almost a total lack of visual phenomena... no wave-forms, color distortion or object shape changes, and no eyes-closed imagery, unlike most N,N-disubstituted tryptamines."<ref name="TiHKAL">{{cite book|title=TiHKAL: The Continuation|title-link=TiHKAL|last1=Shulgin|first1=Alexander|last2=Shulgin|first2=Ann|author-link1=Alexander Shulgin|year=1997|publisher=Transform Press|location=United States|isbn=0-9630096-9-9|oclc=38503252|chapter-url=https://erowid.org/library/books_online/tihkal/tihkal47.shtml|chapter=#47. MIPT}}</ref>
Today, MiPT remains relatively uncommon and is either used as a recreational or an [[entheogenic]] substance. It has been distributed online as a [[research chemical]]. Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPT in humans, and it has little history of human usage.
==Chemistry==
==Chemistry==
{{chemistry}}
MiPT, or N-methyl-N-isopropyltryptamine, is a synthetic indole molecule of the [[tryptamine]] class. Tryptamines share a core structure that comprises a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. Unlike [[DMT]], which contains two methyl groups, MiPT contains groups of one methyl and one isopropyl carbon chains bound to the terminal amine RN of its tryptamine backbone. MiPT is the methyl analog of [[DiPT]].
==Pharmacology==
==Pharmacology==
{{Main|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
Like with most [[psychedelic]] tryptamines, MiPT is thought to act principally as a [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] [[Agonist#Agonists|partial agonist]]. The psychedelic effects are believed to come from MiPT's binding efficacy at the 5-HT<sub>2A</sub> receptors.
Like with most [[psychedelic]] tryptamines, MiPT is thought to act principally as a [[Serotonin#The_5-HT_system|5-HT<sub>2A</sub>]] [[Agonist#Agonists|partial agonist]]. The psychedelic effects are believed to come from MiPT's binding efficacy at the 5-HT<sub>2A</sub> receptors.
However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
However, the role of these interactions and how it results in the psychedelic experience continues to remain elusive.
==Subjective effects==
==Subjective effects==
{{effectStub}}
The sensory effects of MiPT are said to be similar to those of DiPT but with less intensity at the same dose, and without the same bias towards producing auditory distortions.
{{Preamble/SubjectiveEffects}}
{{Preamble/SubjectiveEffects}}
The sensory effects of MiPT are said to be similar to those of DiPT but with less intensity at the same dose.
*'''[[Effect::Drifting]]''' ''([[Drifting#Melting|melting]], [[Drifting#Breathing|breathing]], [[Drifting#Morphing|morphing]] and [[Drifting#Flowing|flowing]])''
*'''[[Effect::Drifting]]''' ''([[Drifting#Melting|melting]], [[Drifting#Breathing|breathing]], [[Drifting#Morphing|morphing]] and [[Drifting#Flowing|flowing]])''
*'''[[Effect::Colour shifting]]'''
*'''[[Effect::Colour shifting]]'''
*'''[[Effect::Depth perception distortions]]'''
*'''[[Effect::Perspective distortions]]'''
*'''[[Effect::Symmetrical texture repetition]]'''
*'''[[Effect::Tracers]]'''
*'''[[Effect::Tracers]]'''
*'''[[Effect::After images]]'''
*'''[[Effect::Brightness alteration]]'''
*'''[[Effect::Brightness alteration]]'''
*'''[[Effect::Diffraction]]'''
===[[Effect::Geometry]]===
}}
|{{effects/cognitive|
====Hallucinatory states====
The cognitive effects of MiPT are reported to be mild for a psychedelic. Rather than producing distinct perceptual distortions, it is reported instead to act as a mild sensory amplifier.
*'''[[Effect::Transformations]]'''
*'''[[Effect::Internal hallucinations]]''' (''[[effect::autonomous entities]]''; ''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'')
*'''[[Effect::Auditory enhancement|Enhancements]]''' - MiPT has been reported to notably enhance auditory sensation, which stands in contrast to the relatively weak visual changes it produces.
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
|-
The toxicity and long-term health effects of recreational MiPT use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. This is because MiPT is a [[research chemical]] with very little history of human usage.
| [[File:Lolol.png|17px]]''Main articles: [[Research chemicals#Toxicity and harm potential|Research chemicals § Toxicity and harm potential]]'' ''&'' ''[[Responsible use #Hallucinogens|Responsible use § Hallucinogens]]''
|}
Anecdotal evidence from those who have tried MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
The toxicity and long-term health effects of recreational MiPT use do not seem to have been studied in any scientific context and the exact [[Toxicity::toxic dose is unknown]]. This is because MiPT is a [[research chemical]] with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug.
As with many psychedelics, the use of MiPT has the potential to bring about long-lasting perceptual and psychological alterations. MiPT is known to chronically alter the perception of sound and talking, which may not be suitable for everyone.
===Tolerance and addiction potential===
===Tolerance and addiction potential===
Line 93:
Line 95:
Tolerance to the effects of MiPT are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). MiPT presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of MiPT all psychedelics will have a reduced effect.
Tolerance to the effects of MiPT are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::3 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::7 days]] to be back at baseline (in the absence of further consumption). MiPT presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of MiPT all psychedelics will have a reduced effect.
==Legal issues==
==Legal status==
Due to its relative obscurity, the possession and sale of MiPT is unscheduled in most countries.
Due to its relative obscurity, the possession and sale of MiPT is unscheduled in most countries.
*'''United Kingdom''' - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.<ref>Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted</ref>
*'''Germany''': MiPT is controlled under the NpSG (''New Psychoactive Substances Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref> as of July 18, 2019.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf|title=Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27|pages=1083-1094|publication-date=July 17, 2019|access-date=January 1, 2020|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]|access-date=December 10, 2019|language=de}}</ref>
*'''USA''' - MiPT is unscheduled in the United States. It may be considered controlled as an analog of another stimulant, alpha-methyl-tryptamine, but this has not been tested in court.
*'''Switzerland''': MiPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''': MiPT is a Class A controlled substance in the United Kingdom as a result of the tryptamine catch-all clause.<ref>{{cite web|title=Part I: Class A Drugs|url=http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I|work="Misuse of Drugs Act 1971"|access-date=January 7, 2020|publisher=UK Government}}</ref>
*'''United States''': MiPT is unscheduled in the United States. It may be considered an analogue of [[DMT]], which is a Schedule I compound under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.{{citation needed}}
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
N-Methyl-N-isopropyltryptamine (also known as MiPT) is a lesser-known psychedelic substance of the tryptamine class that produces psychedelic effects when administered. It is structurally related to tryptamines like DMT, DiPT, and MET, although it is reported to produce qualitatively different effects. Its effects are generally described as mild, indistinct, and highly variable between users. In contrast to many related tryptamines, it is able to be taken orally.
MiPT was first synthesized and investigated by Alexander Shulgin and described in his book TiHKAL ("Tryptamines I Have Known and Loved"). In the commentary, Shulgin notes that "there is almost a total lack of visual phenomena... no wave-forms, color distortion or object shape changes, and no eyes-closed imagery, unlike most N,N-disubstituted tryptamines."[1]
Today, MiPT remains relatively uncommon and is either used as a recreational or an entheogenic substance. It has been distributed online as a research chemical. Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPT in humans, and it has little history of human usage.
MiPT, or N-methyl-N-isopropyltryptamine, is a synthetic indole molecule of the tryptamine class. Tryptamines share a core structure that comprises a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. Unlike DMT, which contains two methyl groups, MiPT contains groups of one methyl and one isopropyl carbon chains bound to the terminal amine RN of its tryptamine backbone. MiPT is the methyl analog of DiPT.
Like with most psychedelic tryptamines, MiPT is thought to act principally as a 5-HT2Apartial agonist. The psychedelic effects are believed to come from MiPT's binding efficacy at the 5-HT2A receptors.
However, the role of these interactions and how it results in the psychedelic experience continues to remain elusive.
Subjective effects
The sensory effects of MiPT are said to be similar to those of DiPT but with less intensity at the same dose, and without the same bias towards producing auditory distortions.
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
The cognitive effects of MiPT are reported to be mild for a psychedelic. Rather than producing distinct perceptual distortions, it is reported instead to act as a mild sensory amplifier.
Enhancements - MiPT has been reported to notably enhance auditory sensation, which stands in contrast to the relatively weak visual changes it produces.
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
The toxicity and long-term health effects of recreational MiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because MiPT is a research chemical with very little history of human usage.
Anecdotal evidence from those who have tried MiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
MiPT is not habit-forming and the desire to use it can actually decrease with regular consumption. Like with most psychedelics, it is most often thought to be self-regulating.
Tolerance to the effects of MiPT are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). MiPT presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of MiPT all psychedelics will have a reduced effect.
Legal status
Due to its relative obscurity, the possession and sale of MiPT is unscheduled in most countries.
Germany: MiPT is controlled under the NpSG (New Psychoactive Substances Act)[2] as of July 18, 2019.[3] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[4]
Switzerland: MiPT is not controlled under Buchstabe A, B, C and D. It could be considered legal.[5]
United Kingdom: MiPT is a Class A controlled substance in the United Kingdom as a result of the tryptamine catch-all clause.[6]
United States: MiPT is unscheduled in the United States. It may be considered an analogue of DMT, which is a Schedule I compound under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.[citation needed]
↑"Anlage NpSG" (in Deutsch). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
↑"§ 4 NpSG" (in Deutsch). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
